Arcus Biosciences Inc. and Strata Oncology Inc. entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus’s clinical-stage anti-PD-1 antibody, in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy.
Collage art of mammograms of dense breastsIllustrator: Cyrus FineganWhile breast cancer experts are anything but clear on what the words “dense breasts” signify in the clinic, or for that matter, in the English language, FDA appears to be less perplexed.
